We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Pathway That Enables Movement of Metastatic Cancer Cells Identified

By LabMedica International staff writers
Posted on 16 Oct 2011
Cancer researchers have identified a molecular pathway that seems to be responsible for the ability of metastatic tumor cells to change shape and travel.

Investigators at the University of Michigan (Ann Arbor, USA) worked with breast cancer cells growing in culture. Previous studies had shown that aggressively metastatic breast cancer cells usually overexpressed the RhoC (aplysia ras-related homolog 9) gene. In this study, they searched for the molecular trigger for RhoC expression.

They reported in the August 23, 2011, online edition of the journal Cancer Research that the protein p38gamma was directly linked to RhoC activation. P38gamma is one member of the p38 MAPK (p38 mitogen-activated protein kinase) class of mitogen-activated protein kinases. These enzymes are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.

Results from experiments with breast cancer cell cultures revealed that inactivation of p38gamma caused cells to flatten out and shift from fast motion to ineffective movement. Clinical relevance indicated that elevated expression of p38gamma was associated with lower overall survival of breast cancer patients. The critical role of p38gamma was further emphasized by data generated from a mathematical model that described how various molecules contributed to cell movement.

“Normal motion is commonly seen in aggressive cancers, which is why it is very important to understand what the key switches are for this motion,” said senior author Dr. Sofia Merajver, professor of internal medicine at the University of Michigan. “Cell movement is very difficult to observe, which is why mathematical modeling in oncology is valuable. This gives us a more complete understanding of how aggressive breast cancer cells move and the influence of p38gamma in particular on modifying this motion.”

“We do have targeted therapies in the clinic, but the total burden of disease that they ameliorate is still relatively minimal. The reasons may not necessarily be that they are not good drugs, but simply that we do not understand how they work, because we do not understand the biology in sufficient detail. That’s why studies like this are so important in advancing drug development,” said Dr. Merajver.

Related Links:
University of Michigan



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test monitors blood levels of DNA fragments released by dying tumor cells (Photo courtesy of 123RF)

Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer

Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.